(-0.02%) 5 212.50 points
(-0.02%) 39 021 points
(-0.01%) 18 198 points
(-1.40%) $77.28
(0.23%) $2.21
(-0.37%) $2 315.70
(-0.70%) $27.35
(-1.07%) $977.80
(0.13%) $0.931
(0.42%) $10.95
(0.27%) $0.802
(-0.92%) $90.60
Quarter results today
(bmo 2024-05-08)
Expected move: +/- 4.34%
Live Chart Being Loaded With Signals
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches...
Stats | |
---|---|
本日の出来高 | 171 244 |
平均出来高 | 682 219 |
時価総額 | 11.67B |
EPS | INR0 ( 2024-01-22 ) |
次の収益日 | ( INR0 ) 2024-07-30 |
Last Dividend | INR0.500 ( 2023-07-12 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 13.43 |
ATR14 | INR0.0730 (0.07%) |
ボリューム 相関
Bliss GVS Pharma Limited 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Bliss GVS Pharma Limited 相関 - 通貨/商品
Bliss GVS Pharma Limited 財務諸表
Annual | 2022 |
収益: | INR7.52B |
総利益: | INR3.50B (46.60 %) |
EPS: | INR6.83 |
FY | 2022 |
収益: | INR7.52B |
総利益: | INR3.50B (46.60 %) |
EPS: | INR6.83 |
FY | 2022 |
収益: | INR7.38B |
総利益: | INR3.47B (47.02 %) |
EPS: | INR2.24 |
FY | 2021 |
収益: | INR5.69B |
総利益: | INR2.40B (42.16 %) |
EPS: | INR6.64 |
Financial Reports:
No articles found.
Bliss GVS Pharma Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0.500 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.300 | 2010-11-25 |
Last Dividend | INR0.500 | 2023-07-12 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 19 | -- |
Total Paid Out | INR9.35 | -- |
Avg. Dividend % Per Year | 0.46% | -- |
Score | 2.17 | -- |
Div. Sustainability Score | 4.34 | |
Div.Growth Potential Score | 4.25 | |
Div. Directional Score | 4.30 | -- |
Year | Amount | Yield |
---|---|---|
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR1.000 | 0.48% |
2019 | INR1.000 | 0.61% |
2020 | INR0.500 | 0.34% |
2021 | INR1.000 | 0.49% |
2022 | INR1.000 | 0.96% |
2023 | INR0.500 | 0.69% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
STARPAPER.NS | Dividend Junior | 2023-09-15 | Sporadic | 22 | 1.19% | |
MUNJALAU.NS | Dividend Junior | 2023-08-24 | Sporadic | 19 | 1.47% | |
HINDCOMPOS.NS | Dividend Junior | 2023-09-22 | Annually | 23 | 0.50% | |
BODALCHEM.NS | Dividend Junior | 2023-09-22 | Annually | 14 | 0.38% | |
RELAXO.NS | Dividend Junior | 2023-08-17 | Annually | 14 | 0.17% | |
KRBL.NS | Dividend Junior | 2023-08-25 | Annually | 23 | 0.61% | |
FCL.NS | Dividend Junior | 2023-09-08 | Annually | 10 | 0.22% | |
ANANTRAJ.NS | Dividend Junior | 2023-06-27 | Annually | 18 | 0.22% | |
TATACOFFEE.NS | Dividend Junior | 2023-05-15 | Annually | 23 | 0.85% | |
NIACL.NS | No Dividend Player | 2023-09-07 | Sporadic | 7 | 0.44% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.116 | 1.500 | 7.68 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.129 | 1.500 | 9.68 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 12.33 | 1.000 | 6.54 | 6.54 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.70 | 2.00 | 9.10 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.70 | 2.00 | 8.65 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.477 | 1.000 | 5.38 | 5.38 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.165 | 1.000 | 8.69 | 8.69 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.34 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.40 | 1.000 | 8.75 | 0 | [1 - 100] |
returnOnEquityTTM | 0.129 | 2.50 | 9.79 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.70 | 2.00 | 9.10 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.444 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.70 | 2.00 | 9.10 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0364 | 1.500 | -3.09 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0373 | 1.000 | -1.566 | 0 | [0.1 - 0.5] |
Total Score | 4.25 |
Bliss GVS Pharma Limited
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, it offers therapeutic products consisting of anti-bacterial, anti-dandruff shampoo, amino acid preparation, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as medicated, complexion, moisturizing, and total protection soaps. The company also exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。